Plasma levels and hepatic mRNA expression of transforming growth factor-β1 in patients with fulminant hepatic failure
- 30 November 1997
- journal article
- Published by Elsevier in Journal of Hepatology
- Vol. 27 (5), 780-788
- https://doi.org/10.1016/s0168-8278(97)80313-3
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Plasma hepatocyte growth factor and biliprotein levels and outcome in fulminant hepatic failureJournal of Hepatology, 1994
- Increased transforming growth factor-β1 gene expression in human liver diseaseJournal of Hepatology, 1992
- Transforming Growth Factors β1 and α in Chronic Liver DiseaseNew England Journal of Medicine, 1991
- Thrombin—antithrombin III complex in fulminant hepatic failure: evidence for disseminated intravascular coagulation and relationship to outcomeEuropean Journal of Clinical Investigation, 1990
- ENHANCED TUMOUR NECROSIS FACTOR AND INTERLEUKIN-1 IN FULMINANT HEPATIC FAILUREThe Lancet, 1988
- Type beta transforming growth factor reversibly inhibits the early proliferative response to partial hepatectomy in the rat.Proceedings of the National Academy of Sciences, 1988
- Transforming growth factor β inhibits DNA synthesis in hepatocytes isolated from normal and regenerating rat liverBiochemical and Biophysical Research Communications, 1987
- Cell-cycle regulation of histone gene expressionCell, 1986
- Inhibitory effect of transforming growth factor-β on DNA synthesis of adult rat hepatocytes in primary cultureBiochemical and Biophysical Research Communications, 1985
- Fulminant Hepatitis: Mayo Clinic Experience With 34 CasesMayo Clinic Proceedings, 1985